Test Price
700 AED✅ Home Collection Available
Cultured AFB Antitubercular DST Linezolid Test in UAE | 700 AED | DHA-Approved Drug Resistance Profiling
Executive Summary & Core Metrics
The Cultured AFB Antitubercular DST Linezolid Test delivers definitive phenotypic susceptibility profiling of Mycobacterium tuberculosis complex against linezolid using automated fluorescent technology (MGIT 960 / BACTEC platform). With a diagnostic sensitivity exceeding 99% for detecting linezolid resistance, this assay directly measures bacterial response to the drug rather than inferring resistance from genetic markers alone. The test is performed at our DHA-licensed facility (License No. 1143) in Dubai Healthcare City under ISO 9001:2015 quality standards. Results are available within 21 days from receipt of a pure culture isolate, enabling precise therapeutic selection for drug-resistant tuberculosis (DR-TB).
Test Overview & Methodology
This assay determines the minimum inhibitory concentration (MIC) of linezolid against a pure isolate of Mycobacterium tuberculosis complex using the automated fluorescent broth-based method. The MGIT 960 system continuously monitors fluorescence signals proportional to oxygen consumption, providing a quantitative resistance profile with enhanced reproducibility compared to conventional solid-media proportion methods. Phenotypic DST remains the gold standard for guiding linezolid therapy in multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).
| Feature | Our Test (DHA-Approved) | Alternative (Routine DST) |
|---|---|---|
| Methodology | Automated Fluorescent DST (MGIT 960 / BACTEC) | Manual Proportion Method (LJ medium) |
| Analytical Sensitivity | ≥99% for Linezolid Resistance Detection | ~90%, may miss low-level resistance |
| Turnaround Time | 21 days from pure isolate receipt | 28–42 days |
| ISO / DHA Compliance | DHA Licensed & ISO 9001:2015 Certified | Variable |
Physician Insight & Safety Protocols
"Phenotypic DST for linezolid in Mycobacterium tuberculosis provides the most reliable evidence for tailoring treatment regimens in drug-resistant cases. The automated fluorescent system offers standardized MIC determination that correlates well with clinical outcomes. However, the result must always be integrated with the patient's treatment history, radiographic evolution, and sputum conversion status. A single susceptibility report should never replace multidisciplinary clinical evaluation."
— Dr. Ajay Singh, General Practitioner | DHA Registration ID: 36234132
Medication Advisory
Patients currently prescribed linezolid must not alter or discontinue their medication based solely on interim laboratory findings. Adjustments to antitubercular therapy require careful correlation with clinical status, adverse effect monitoring, and specialist supervision. Premature modification of the regimen may compromise treatment efficacy and contribute to acquired drug resistance.
Patient Safety Exclusion Criteria
- Patient has received linezolid therapy for fewer than 14 days at the time of isolate collection, which may produce falsely susceptible results.
- Suboptimal specimen quality: mixed microbial growth, culture contamination, or insufficient bacterial biomass for valid DST.
- Absence of confirmed active tuberculosis disease — this test requires a pure M. tuberculosis complex isolate with documented clinical correlation.
Emergency Red Flags — Seek immediate medical attention if you experience:
- Sudden high fever accompanied by rigors
- Massive hemoptysis (exceeding 30 mL of blood)
- Acute chest pain or progressive dyspnea
- Altered consciousness or new-onset seizures
Patient FAQ & Clinical Guidance
1. How does phenotypic linezolid DST differ from molecular resistance testing?
A: Phenotypic DST directly measures the organism's growth response to linezolid, capturing both known and novel resistance mechanisms. Molecular assays detect only predefined genetic mutations (e.g., in rplC or rldD), potentially missing low-level or emerging resistance. Our automated fluorescent method achieves over 99% sensitivity for phenotypic resistance detection.
2. Can this test be performed if the patient has already started linezolid therapy?
A: The test requires a pure culture isolate obtained before significant drug exposure. Specimens collected after 14 or more days of linezolid therapy may underestimate resistance due to drug selection pressure. Coordinate collection timing carefully with your treating physician to ensure valid results.
3. What specimen type is required and how is it transported to the laboratory?
A: The test requires a sterile pure culture isolate of Mycobacterium tuberculosis complex in a screw-capped transport container. For new patients without an existing isolate, a primary sputum specimen can be collected at our facility or via our home collection service (available daily from 8 AM to 11 PM). The specimen is then cultured to obtain the isolate required for DST.
4. What clinical decisions does the linezolid DST result inform?
A: The MIC value guides the inclusion and dosing of linezolid in individualized MDR-TB and XDR-TB treatment regimens. A susceptible result supports continued use; resistance indicates the need for alternative agents. The report also contributes to surveillance data for regional antimicrobial resistance patterns.
UAE Regulatory & Data Privacy Adherence
All laboratory procedures and data handling are conducted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Patient information is encrypted in transit and at rest, accessible only to authorized healthcare professionals directly involved in diagnostic reporting and clinical consultation.
Clinical & Logistical Metadata
| Test Name | Cultured AFB Antitubercular DST Linezolid |
| Price (AED) | 700 AED |
| Turnaround Time | 21 days from receipt of pure culture isolate |
| Sample Type / Matrix | Pure culture isolate of Mycobacterium tuberculosis complex (primary specimen: sputum or bronchoalveolar lavage) |
| Methodology Used | Automated Fluorescent DST (MGIT 960 / BACTEC platform) |
| ICD-10-CM Code | A15.0, Z16.31 |
| LOINC Code | 100342-9 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians